Co-Diagnostics (CODX) Q1 2026 Earnings Transcript

Co-Diagnostics reported Q1 revenue of $146,000, up from $50,000, but still generated a $9.1 million net loss and $8.7 million adjusted EBITDA loss as it continued heavy investment in R&D and commercialization. Management said it expects to file FDA clearance for its upper respiratory multiplex test in the third quarter, while CoSara received a CDSCO manufacturing license for PCR Pro and expanded its South Asia TAM to about $13 billion. The company also reiterated that additional capital will likely be needed and is evaluating a potential SPAC or similar transaction for CoSara.

Analysis

CODX is still in the classic “promise outruns monetization” phase, but the sequencing matters: the company is now stacking multiple catalysts that could re-rate the stock before any meaningful revenue inflection. The most important setup is that the next 2-3 quarters are a binary window for regulatory optionality in the U.S. and India; if the respiratory submission lands and TB moves into local studies on schedule, the market will likely shift from valuing CODX as a cash-burning R&D story to a platform with multiple shots on goal.

The second-order effect is that localization in India and Saudi Arabia is less about near-term margins than about preserving bargaining power. If CoSara and CoMira can credibly manufacture regionally, CODX can reduce dependence on U.S.-centric distribution economics and create a moat against centralized PCR incumbents that are structurally weaker in low-infrastructure settings. That said, the business still has the profile of a funding treadmill: the cash runway is short relative to development intensity, so any delay in regulatory progress likely forces dilutive capital raises before commercialization can de-risk the story.

The contrarian view is that the market may be underestimating how much of the valuation can be pulled forward by optionality around a SPAC or partial monetization of CoSara, even if the core consolidated business remains loss-making. But that same optionality cuts both ways: if management cannot convert the NDA/data-room process into a credible transaction, investors are left with a subscale diagnostics platform facing financing needs and execution risk across three geographies. In other words, the stock can work on narrative momentum, but the underwriting still depends on a very tight cadence of milestone delivery over the next 6-9 months.

Key Decisions for Investors

• Speculative long CODX into the next 1-2 regulatory milestones; size small and treat as event-driven optionality. Upside is a 30-60% re-rating if FDA submission and India TB timing hold, but downside is similarly sharp if timelines slip or a capital raise lands sooner than expected.
• Buy CODX calls rather than stock for the 3-6 month window if liquidity allows; the setup is favorable for convexity because dilution risk caps equity upside while milestone headlines can gap the name. Prefer structures that limit premium at risk.
• Pair trade: long CODX / short a larger-cap diagnostics or instruments basket on a relative-value basis only if looking for milestone-specific alpha. The thesis is not sector beta; it is that CODX has more binary catalyst density than the broader group.
• If CODX rallies sharply on transaction chatter around CoSara, use strength to reduce exposure unless a deal is signed. The SPAC optionality is a classic source of over-earnest forward multiple expansion before any hard cash outcome exists.
• Avoid holding an outsized position through any financing window unless the company pre-funds execution; the highest-probability failure mode is not scientific invalidation but dilution before commercialization.